Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Katarina Raslova. (2010) An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog. Vascular Health and Risk Management 6, pages 399-410.
Read now
Read now
Jean-Pierre Le Floch. (2010) Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics. Diabetes, Metabolic Syndrome and Obesity 3, pages 197-213.
Read now
Read now
Odd Erik Johansen, Pål Johan Vanberg, Bente Kvarv Kilhovd & Anders Palmstrøm Jørgensen. (2009) Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia. Vascular Health and Risk Management 5, pages 121-128.
Read now
Read now
Allen B King. (2009) Insulin detemir: a better basal insulin for the management of diabetes?. Expert Review of Endocrinology & Metabolism 4:1, pages 15-23.
Read now
Read now
Kristin Eckardt & Jürgen Eckel. (2008) Insulin analogues: Action profiles beyond glycaemic control. Archives of Physiology and Biochemistry 114:1, pages 45-53.
Read now
Read now
Articles from other publishers (16)
Johan Jendle, Åsa Ericsson, Barnaby Hunt, William J. Valentine & Richard F. Pollock. (2017) Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden. Diabetes Therapy 9:1, pages 87-99.
Crossref
Crossref
Marcin Czech, Elżbieta Rdzanek, Justyna Pawęska, Olga Adamowicz-Sidor, Maciej Niewada & Michał Jakubczyk. (2015) Drug-related risk of severe hypoglycaemia in observational studies: a systematic review and meta-analysis. BMC Endocrine Disorders 15:1.
Crossref
Crossref
B. M. Frier, D. Russell-Jones & T. Heise. (2013) A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review. Diabetes, Obesity and Metabolism 15:11, pages 978-986.
Crossref
Crossref
Michèle Sennhauser & Peter Zweifel. (2014) Ist ein neues Arzneimittel sein Geld wert? Wessen Geld? – Bewertung eines neuen Diabetes-Präparats mit Hilfe eines Discrete-Choice-Experiments. PharmacoEconomics German Research Articles 11:2, pages 45-63.
Crossref
Crossref
Annelie Carlsson, Gun Forsander, Johnny Ludvigsson, Sara Larsen & Eva Örtqvist. (2013) A multicenter observational safety study in Swedish children and adolescents using insulin detemir for the treatment of type 1 diabetes. Pediatric Diabetes 14:5, pages 358-365.
Crossref
Crossref
Zafar A. Latif, Zanariah Hussein, Leon Litwak, Nabil El Naggar, Jian-Wen Chen & Pradana Soewondo. (2013) Safety and Effectiveness of Insulin Aspart in Basal-Bolus Regimens Regardless of Age: A1chieve Study Results. Diabetes Therapy 4:1, pages 103-118.
Crossref
Crossref
Pradana Soewondo, Ida Ayu Kshanti, R. Bowo Pramono, Yuanita Asri Langi & Tjokorda Gde Dalem-Pemayun. (2013) Clinical experience with insulin detemir: Results from the Indonesian cohort of the international A1chieve study. Diabetes Research and Clinical Practice 100, pages S47-S53.
Crossref
Crossref
Gillian M. Keating. (2012) Insulin Detemir. Drugs 72:17, pages 2255-2287.
Crossref
Crossref
Kazuhiko Jinno, Tatsuhiko Urakami, Reiko Horikawa, Tomoyuki Kawamura, Nobuyuki Kikuchi, Tohru Kikuchi, Rika Kizu, Kitaro Kosaka, Haruo Mizuno, Takahiro Mochizuki, Aki Nishii, Yukashi Ohki, Shun Soneda, Shigetaka Sugihara, Toshi Tatematsu & Shin Amemiya. (2012) Usefulness of insulin detemir in Japanese children with type 1 diabetes. Pediatrics International 54:6, pages 773-779.
Crossref
Crossref
Asako Nishimura, Taro Hayakawa, Yu Yamamoto, Mami Hamori, Keiko Tabata, Keiko Seto & Nobuhito Shibata. (2012) Controlled release of insulin from self-assembling nanofiber hydrogel, PuraMatrix™: Application for the subcutaneous injection in rats. European Journal of Pharmaceutical Sciences 45:1-2, pages 1-7.
Crossref
Crossref
Taro Hayakawa, Michiyo Ishii, Megumi Watanabe, Hiroya Iwase, Asako Nishimura, Takako Monden, Kenji Kamiuchi, Motohide Isono & Nobuhito Shibata. (2011) Replacement of neutral protamine Hagedorn insulin with the long-acting insulin analogue, detemir, improves glycemic control without weight gain in basal-bolus insulin therapy in Japanese patients with type 1 diabetes. Journal of Diabetes Investigation 2:1, pages 71-77.
Crossref
Crossref
Virginia Valentine. (2010) Insulin Initiation During a 20-Minute Office Visit: Part 2: Making It Happen. Diabetes Spectrum 23:4, pages 260-266.
Crossref
Crossref
M. Marre, M. Pinget, H. Gin, C. Thivolet, H. Hanaire, J.-J. Robert & P. Fontaine. (2009) Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE™ study in a cohort of French patients with type 1 or type 2 diabetes. Diabetes & Metabolism 35:6, pages 469-475.
Crossref
Crossref
Selim Kurtoglu, Mehmet Emre Atabek, Ceyhun Dizdarer, Ozgur Pirgon, Pinar Isguven & Sevil Emek. (2009) Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE™ observational study. Pediatric Diabetes 10:6, pages 401-407.
Crossref
Crossref
S. Sreenan, A. Virkamäki, K. Zhang & J. B. Hansen. (2008) Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE™ study. International Journal of Clinical Practice 62:12, pages 1971-1980.
Crossref
Crossref
. (2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:9.
Crossref
Crossref